Skip to content
Abobotulinumtoxina
Dysport (abobotulinumtoxina) is an unknown pharmaceutical. Abobotulinumtoxina was first approved as Dysport on 2009-04-29. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and hyperhidrosis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dysport
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abobotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
DysportabobotulinumtoxinAIpsen Biopharm LimitedN-125274 RX2009-04-29
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
dysport Biologic Licensing Application2023-01-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
blepharospasmD001764G24.5
dystoniaHP_0001332D004421G24
fissure in anoHP_0012390D005401K60.2
genetic skin diseasesD012873
hyperhidrosisHP_0000975D006945
muscle rigidityHP_0002063D009127
strabismusHP_0000486D013285H50.2
Agency Specific
FDA
EMA
Expiration
Code
abobotulinumtoxina, Dysport, Ipsen Biopharm Limited
2023-07-29Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J0586
Injection, abobotulinumtoxina, 5 units
Clinical
Clinical Trials
89 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8411147
AnesthesiaD00075822116
ObesityD009765EFO_0001073E66.9112
Postoperative nausea and vomitingD020250EFO_000488811
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1124
Coronary artery diseaseD003324I25.1213
Coronary artery bypassD001026EFO_000377622
Post-cardiac arrest syndromeD00008094211
Coronary diseaseD00332711
Panic disorderD016584EFO_0004262F41.0111
Post-traumatic stress disordersD013313EFO_0001358F43.1111
Pulmonary embolismD011655EFO_0003827I2611
Postoperative cognitive complicationsD00007969011
Diabetic retinopathyD003930EFO_000377011
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.94216
Idiopathic pulmonary fibrosisD054990J84.112123
Non-small-cell lung carcinomaD0022891113
Brain hypoxia-ischemiaD020925EFO_1000846P91.61213
Respiration disordersD012120J00-J99222
Covid-19D000086382U07.1112
VapingD0000721371112
Bronchiolitis obliteransD001989EFO_00071831112
Colorectal neoplasmsD01517911
DeliriumD003693R41.011
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171EFO_0003818J98.4112
Bipolar disorderD001714EFO_0000289F30.911
Major depressive disorderD003865EFO_0003761F2211
Alzheimer diseaseD000544EFO_0000249F0311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature birthD047928EFO_0003917O6011
Bronchopulmonary dysplasiaD001997P27.811
EmphysemaD004646EFO_0000464J4311
CholelithiasisD002769EFO_0004799K8011
CholecystitisD002764HP_0001082K8111
Brain diseasesD001927HP_0001298G93.4011
Marijuana smokingD00838511
Marijuana useD00007460911
Lung injuryD055370S27.3011
InfectionsD007239EFO_000054411
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameABOBOTULINUMTOXINA
INN
Description
Botulinum toxin, or botulinum neurotoxin (BoNT), is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It is also known as Botulin, the density of which is predicted to be 1.5±0.1 g/cm3. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
Classification
Neurotoxin
Drug class
Image (chem structure or protein)ABOBOTULINUMTOXINA
Structure (InChI/SMILES or Protein Sequence)
>2VU9:A|BOTULINUM NEUROTOXIN A HEAVY CHAIN MGSSHHHHHHSSGLVPRGSHMDTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIV YNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINR WIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSN SGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNI VRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFH QFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLQ
Identifiers
PDB2G7P, 2VU9, 2VUA, 3BTA, 3DDA, 3DDB, 3DS9, 3DSE, 3FUO, 3K3Q, 3QIX, 3QIY, 3QIZ, 3QJ0, 3QW5, 3QW6, 3QW7, 3QW8, 3ZUR, 3ZUS, 4EJ5, 4EL4, 4ELC, 4HEV, 4IQP, 4JRA, 4KS6, 4KTX, 4KUF, 4ZJX, 5JLV, 5JMC, 5L21, 5MK6, 5MK7, 5MOY, 5TPB, 5TPC, 5V8P, 5V8R, 5V8U, 5VGV, 5VGX, 6DKK, 6ES1, 6MHJ, 6XCB, 6XCC, 6XCD, 6XCE, 6XCF, 7N18
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108570
ChEBI ID
PubChem CID
DrugBankDB00083
UNII ID
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,539 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dysport
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details